A major abortion-related case is likely to reach the U.S. Supreme Court, and it may feel familiar to those following the issue. Louisiana is among several states seeking to limit access to telehealth abortions, a method that accounts for about 30 percent of all abortions in the U.S. Telehealth allows patients to receive abortion medication via mail after a virtual consultation with a healthcare provider, making it harder for states with strict abortion bans to enforce their laws. Louisiana is challenging the Food and Drug Administration (FDA) over its 2023 decision to allow telehealth access to mifepristone, one of the two pills used in medication abortions. The state also claims that the FDA’s rules violate the Comstock Act, an old 19th-century law against distributing "obscene" materials, which Louisiana says effectively acts as a nationwide abortion ban. Louisiana previously asked the 5th U.S. Circuit Court of Appeals to block telehealth access to mifepristone, but the Supreme Court rejected that request last spring, allowing access to remain unchanged until further legal action. Now, Louisiana is making the same request again, even though the Supreme Court explicitly said the state could not have immediate relief. The state is trying to avoid a legal pitfall that previously blocked anti-abortion groups from filing lawsuits. In an earlier case, the Supreme Court found that the plaintiffs lacked legal standing, or the right to sue. Louisiana argues it is different because it has already spent money on treating complications from mifepristone use and is struggling to enforce its own abortion ban. The case is also linked to the Trump administration, which has been reviewing mifepristone’s safety. Louisiana wants the 5th Circuit to pause access to the drug immediately while the review is ongoing, but the court has not agreed. The Supreme Court’s earlier decision suggests that mifepristone access should stay the same during the legal process. Louisiana, however, continues to push for immediate action, arguing that the Supreme Court’s earlier order was not binding. The outcome of the case remains uncertain, but the 5th Circuit panel assigned to the case is known for being relatively left-leaning, which may not favor Louisiana’s position. Looking ahead, the Trump administration may still be cautious about imposing new restrictions on mifepristone before the midterm elections, where abortion remains a politically sensitive issue. After the election, however, the administration may feel more free to act, especially if it wants to appease conservative Christian donors and supporters. Meanwhile, other states, like Texas and Florida, are also challenging mifepristone in court, seeking to remove it from the market entirely. The legal battle over telehealth abortion access is far from over, and the future of mifepristone’s availability remains in question.